Medical device maker Accuray (NSDQ:ARAY) managed to get some Wall Street love after posting a rather harsh 3rd quarter earnings report this week, with investors likely reacting to news of promising order volume growth quarter-over-quarter.
Wall Street Beat
India slashes drug-eluting stent reimbursement by 62% | Wall Street Beat
The Indian government slashed reimbursement rates for drug-eluting stents by more than 61.5%, down to about $460 from roughly $1,200, aiming to give a boost to its domestic stents industry at the expense of the multinational players.
It’s the 2nd rate cut since October 2011, according to the Business Standard. India cut the rate of reimbursement for U.S.-made stents from 65,000 rupees (about $1,200) to 25,000 rupees (~$461), which is now the standard rate for stents regardless of origin, according to the newspaper.
Diabetes: Wall Street cheers Insulet’s spike in sales, narrowed losses
Hologic slips on missed Q2 revenues, lowered outlook
EnteroMedics’ losses soar and shares fall short of Wall Street expectations
Wall Street sent St. Paul, Minn.-based obesity and GI device maker EnteroMedics’ (NSDQ:ETRM) shares down 8% today after the company missed analysts’ consensus estimate.
The strange case of the diabetes market
Abiomed continues rebound, expects to file Impella PMA this fiscal year
Meet the ‘New Covidien’
CardioFocus raises $11M in debt round | Wall Street Beat
CardioFocus added $11 million to its coffers in a round of debt financing from Oxford Finance and Silicon Valley Bank as it commercializes its HeartLight endoscopic ablation system overseas and winds up enrollment in a pivotal U.S. trial.
CardioFocus CRO Renny Clark said the funds will help the company prepare for its submission to the FDA for the HeartLight device, which combines an endoscope and a laser ablation device, according to a press release.
Thoratec shares drop 10% on a harsh 1st quarter report
InVivo expects to raise $10.4M from early warrants call
Massachusetts-based spinal devices maker InVivo Therapeutics (OTC:NVIV) announced an early call for exercise of warrants issued in 2010, expecting to raise $10.4 million.
Under the terms of the warrants, InVivo has the right to call for early exercise because NVIV shares have traded above $2.80 per share for 20 consecutive days, which occurred yesterday.